University of Oklahoma Medical Center
University of Oklahoma Medical Center
Oklahoma City, Oklahoma, United States4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Low Grade Serous Ovarian Cancer | Recruiting | Phase 3 | 2026-10-07 | NCT06072781 | |
| Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function | Arterial Occlusive Diseases, Infarction, Necrosis, Non-ST Elevated Myocardial Infarction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Ventricular Dysfunction, Ventricular Dysfunction, Left, anterolateral myocardial infarction, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, inferior myocardial infarction, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-07-28 | NCT04763200 | |
| Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiovascular disorder, congenital heart disease, heart disorder, hypoplastic left heart syndrome | Active, not recruiting | Phase 1 | 2025-06-27 | NCT04907526 | |
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, low-grade serous ovarian carcinoma, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2025-01-29 | NCT04625270 |